EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

APOE Christchurch‐mimetic therapeutic antibody reduces APOE‐mediated toxicity and tau phosphorylation

Claudia Marino iD, Paula Perez-Corredor, Michael O'Hare, Annie Heuer, Natalia Chmielewska, Harper Gordon, Anita S Chandrahas, Lucia Gonzalez-Buendia, Santiago Delgado-Tirado, Tri H Doan, Timothy E Vanderleest, Said Arevalo-Alquichire und 10 weitere

Alzheimer's & Dementia · 2024-02 · 20 (2) · 819-836

DOI: 10.1002/alz.13436 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 04.10.2023. Verfasst von Claudia Marino und 21 weiteren Autor:innen. Beteiligte Einrichtung: Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology at Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Apolipoprotein E4, Alzheimer Disease. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION We discovered that the APOE3 Christchurch (APOE3Ch) variant may provide resistance to Alzheimer's disease (AD). This resistance may be due to reduced pathological interactions between ApoE3Ch and heparan sulfate proteoglycans (HSPGs). METHODS We developed and characterized the binding, structure, and preclinical efficacy of novel antibodies targeting human ApoE‐HSPG interactions. RESULTS We found that one of these antibodies, called 7C11, preferentially bound ApoE4, a major risk factor for sporadic AD, and disrupts heparin‐ApoE4 interactions. We also determined the crystal structure of a Fab fragment of 7C11 and used computer modeling to predict how it would bind to ApoE. When we tested 7C11 in mouse models, we found that it reduced recombinant ApoE‐induced tau pathology in the retina of MAPT*P301S mice and curbed pTau S396 phosphorylation in brains of systemically treated APOE4 knock‐in mice. Targeting ApoE‐HSPG interactions using 7C11 antibody may be a promising approach to developing new therapies for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein E4Alzheimer DiseaseMiceHumansAnimalsHeparan Sulfate ProteoglycansPhosphorylationApolipoproteins EImmunologic FactorsApolipoprotein E3

Stichwörter der Autor:innen

Alzheimer's diseaseApoEApoE ChristchurchApolipoprotein EHSPGdrug developmentheparan sulfate proteoglycanheparintau phosphorylationtauopathytherapeutic antibody

Substanzen

Apolipoprotein E4Heparan Sulfate ProteoglycansApolipoproteins EImmunologic FactorsApolipoprotein E3

Autor:innen und Institutionen

  • Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology at Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
  • Molecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Gladstone Institute of Neurological Disease, San Francisco, California, USA.

ORCID-Profile: Claudia Marino

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • NIH HHS
  • NEI NIH HHS

Zitieren

APA

Marino, C., Perez-Corredor, P., O'Hare, M., Heuer, A., Chmielewska, N., Gordon, H., Chandrahas, A. S., Gonzalez-Buendia, L., Delgado-Tirado, S., Doan, T. H., Vanderleest, T. E., Arevalo-Alquichire, S., Obar, R. A., Ortiz-Cordero, C., Villegas, A., Sepulveda-Falla, D., Kim, L. A., Lopera, F., Mahley, R., …, & Arboleda-Velasquez, J. F. (2024). APOE Christchurch‐mimetic therapeutic antibody reduces APOE‐mediated toxicity and tau phosphorylation. Alzheimer's & Dementia, 20(2), 819-836. https://doi.org/10.1002/alz.13436

Vancouver

Marino C, Perez-Corredor P, O'Hare M, Heuer A, Chmielewska N, Gordon H, et al. APOE Christchurch‐mimetic therapeutic antibody reduces APOE‐mediated toxicity and tau phosphorylation. Alzheimer's & Dementia. 2024;20(2):819-836. doi:10.1002/alz.13436

BibTeX
@article{Marino2024,
  author = {Marino, Claudia and Perez-Corredor, Paula and O'Hare, Michael and Heuer, Annie and Chmielewska, Natalia and Gordon, Harper and Chandrahas, Anita S and Gonzalez-Buendia, Lucia and Delgado-Tirado, Santiago and Doan, Tri H and Vanderleest, Timothy E and Arevalo-Alquichire, Said and Obar, Robert A and Ortiz-Cordero, Carolina and Villegas, Andres and Sepulveda-Falla, Diego and Kim, Leo A and Lopera, Francisco and Mahley, Robert and Huang, Yadong and Quiroz, Yakeel T and Arboleda-Velasquez, Joseph F},
  title = {APOE Christchurch‐mimetic therapeutic antibody reduces APOE‐mediated toxicity and tau phosphorylation},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {2},
  pages = {819--836},
  doi = {10.1002/alz.13436}
}
Kostenlos starten →